StockNews.com started coverage on shares of Dynatronics (NASDAQ:DYNT – Free Report) in a report issued on Sunday morning. The firm issued a hold rating on the medical equipment provider’s stock.

Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat ...

Stock analysts at StockNews.com initiated coverage on shares of Dynatronics (NASDAQ:DYNT – Get Free Report) in a report released on Saturday. The brokerage set a “hold” rating on the medical equipment ...

Lumbosacral radiculopathy is a neurologic condition that occurs when a nerve root in the lower back is compressed or irritated. Millions of patients suffer from pain due to LSR every year.

The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...

Vertex Pharmaceuticals Incorporated VRTX announced results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR), a disorder that causes pain in the lower back and hip ...

announced results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR), a disorder that causes pain in the lower back and hip that radiates down the back of the thigh ...

The french-fry maker replaced its chief executive and [slashed guidance again]( ...

Hoping to show the drug’s versatility, Vertex also sponsored a mid-stage trial focused on painful “lumbosacral radiculopathy, ...

For 12 weeks, the study followed more than 200 patients with lumbosacral radiculopathy, a nerve condition in the lower back ...

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...